Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm AV, Bak M, Gjerstorff MF, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Leth-Larsen R, Ditzel HJ. Løkkegaard S, et al. Among authors: lindstrom ls. NPJ Breast Cancer. 2021 Jan 4;7(1):2. doi: 10.1038/s41523-020-00210-8. NPJ Breast Cancer. 2021. PMID: 33398005 Free PMC article.
Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS. van 't Veer LJ, et al. Among authors: lindstrom ls. Breast Cancer Res Treat. 2017 Nov;166(2):593-601. doi: 10.1007/s10549-017-4428-9. Epub 2017 Aug 4. Breast Cancer Res Treat. 2017. PMID: 28776283 Free PMC article.
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van't Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, Datnow B, Hasteh F, Krings G, Lin F, Zhang Y, Nordenskjöld B, Stål O, Benz CC, Fornander T, Borowsky AD, Esserman LJ; STO Trialists Group. Lindström LS, et al. J Natl Cancer Inst. 2018 Jul 1;110(7):726-733. doi: 10.1093/jnci/djx270. J Natl Cancer Inst. 2018. PMID: 29361175 Free PMC article.
Assessment of Long-term Distant Recurrence-Free Survival Associated With Tamoxifen Therapy in Postmenopausal Patients With Luminal A or Luminal B Breast Cancer.
Yu NY, Iftimi A, Yau C, Tobin NP, van 't Veer L, Hoadley KA, Benz CC, Nordenskjöld B, Fornander T, Stål O, Czene K, Esserman LJ, Lindström LS. Yu NY, et al. Among authors: lindstrom ls. JAMA Oncol. 2019 Sep 1;5(9):1304-1309. doi: 10.1001/jamaoncol.2019.1856. JAMA Oncol. 2019. PMID: 31393518 Free PMC article.
IP6K2 predicts favorable clinical outcome of primary breast cancer.
Sandström J, Balian A, Lockowandt R, Fornander T, Nordenskjöld B, Lindström L, Pérez-Tenorio G, Stål O. Sandström J, et al. Mol Clin Oncol. 2021 May;14(5):94. doi: 10.3892/mco.2021.2256. Epub 2021 Mar 12. Mol Clin Oncol. 2021. PMID: 33767863 Free PMC article.
Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
Dar H, Johansson A, Nordenskjöld A, Iftimi A, Yau C, Perez-Tenorio G, Benz C, Nordenskjöld B, Stål O, Esserman LJ, Fornander T, Lindström LS. Dar H, et al. Among authors: lindstrom ls. JAMA Netw Open. 2021 Jun 1;4(6):e2114904. doi: 10.1001/jamanetworkopen.2021.14904. JAMA Netw Open. 2021. PMID: 34190995 Free PMC article. Clinical Trial.
Clinical and molecular characteristics of estrogen receptor-positive ultralow risk breast cancer tumors identified by the 70-gene signature.
Johansson A, Yu NY, Iftimi A, Tobin NP, van 't Veer L, Nordenskjöld B, Benz CC, Fornander T, Perez-Tenorio G, Stål O, Esserman LJ, Yau C, Lindström LS. Johansson A, et al. Among authors: lindstrom ls. Int J Cancer. 2022 Jun 15;150(12):2072-2082. doi: 10.1002/ijc.33969. Epub 2022 Mar 7. Int J Cancer. 2022. PMID: 35179782 Free PMC article.
Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.
Johansson A, Dar H, van 't Veer LJ, Tobin NP, Perez-Tenorio G, Nordenskjöld A, Johansson U, Hartman J, Skoog L, Yau C, Benz CC, Esserman LJ, Stål O, Nordenskjöld B, Fornander T, Lindström LS. Johansson A, et al. Among authors: lindstrom ls. J Clin Oncol. 2022 Dec 10;40(35):4071-4082. doi: 10.1200/JCO.21.02844. Epub 2022 Jul 21. J Clin Oncol. 2022. PMID: 35862873 Free PMC article. Clinical Trial.
73 results